Thought Leadership

Latest Report

Obesity matters for drug developers

Close to 40% of the US adult population is now obese and the WHO and AMA define obesity as a disease. So it’s perhaps no surprise that Evaluate Pharma is forecasting sales by indication of $50bn in 2028 and CAGR between 2021 and 2028 at around 36%.  The R&D pipeline is filling up as more and more companies try to grab a slice of this…

Report library

Thumbnail

Evaluate Vantage 2022 Preview Report

Covid-19 will still be a front-page story in 2022, keeping the biopharma sector in the spotlight. The attention will bring some benefits, largely in the shape of broad…

Thumbnail

Biopharma Quarterly Round Up (Q3 2021)

This article pack, produced by the editorial team at Evaluate Vantage, explores the key developments and decisions that are impacting the biopharma landscape. Access…

Thumbnail

Covid Round Up (2021)

The biopharma and medtech sectors have been racing to deliver treatments, vaccines and other solutions to Covid-19 for close to two years now. What progress has been made…

Thumbnail

2021 IASLC World Conference on Lung Cancer

The year-end oncology congress season kicked off with the annual IASLC World Conference on Lung Cancer. While it took place in virtual format from September 8-14, this…